In recent years, the complement system has emerged as an important factor in the pathogenesis of multiple autoimmune neurological conditions, in particular neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG). These findings have opened the door to a new and exciting frontier of treatment possibilities that target the complement system.

Join us as we follow two patient cases through their treatment journey, exploring the role complement plays in the pathophysiology of their debilitating diseases and discussing evidence for new treatment strategies that can be considered for them.

**NEW FRONTIERS IN NEUROLOGY: EMERGING DATA ON THE ROLE OF COMPLEMENT IN AUTOIMMUNE NEUROLOGICAL DISORDERS**

**BY THE END OF THIS WEBINAR, PARTICIPANTS WILL BE ABLE TO:**

1. Define the role of complement in the pathophysiology of autoimmune neurological disorders.

2. Recognize traditional therapies in the treatment of two complement-driven autoimmune neurological diseases, generalized MG (gMG) and NMOSD.

3. Discuss new targeted treatment strategies in difficult-to-treat gMG and NMOSD that can improve patient outcomes by inhibiting the complement system.

For more information, please visit: [http://www.cnsfederation.org/cnsf/cpd/webinars/](http://www.cnsfederation.org/cnsf/cpd/webinars/)

or contact Tara Robson:

tara.robson@antibodyhc.com | 416-319-0225.

This webinar is an accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Neurological Sciences Federation for 1.5 credits. This program was co-developed by the Canadian Neurological Sciences Federation and ANTIBODY Healthcare Communications and was planned to achieve scientific integrity, objectivity and balance. The Webinar was supported by Alexion Pharma Canada who provided an unrestricted grant and in-kind support.